NASDAQ:BFRI Biofrontera (BFRI) Stock Price, News & Analysis $0.85 -0.01 (-0.99%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$0.88 +0.02 (+2.76%) As of 08/28/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Biofrontera Stock (NASDAQ:BFRI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Biofrontera alerts:Sign Up Key Stats Today's Range$0.84▼$0.9250-Day Range$0.60▼$1.1152-Week Range$0.54▼$2.22Volume61,974 shsAverage Volume353,836 shsMarket Capitalization$8.63 millionP/E RatioN/ADividend YieldN/APrice Target$2.75Consensus RatingBuy Company Overview Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. Read More Biofrontera Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreBFRI MarketRank™: Biofrontera scored higher than 62% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBiofrontera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBiofrontera has received no research coverage in the past 90 days.Read more about Biofrontera's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Biofrontera are expected to grow in the coming year, from ($3.01) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biofrontera is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biofrontera is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Biofrontera's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.14% of the float of Biofrontera has been sold short.Short Interest Ratio / Days to CoverBiofrontera has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biofrontera has recently decreased by 17.05%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiofrontera does not currently pay a dividend.Dividend GrowthBiofrontera does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.14% of the float of Biofrontera has been sold short.Short Interest Ratio / Days to CoverBiofrontera has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biofrontera has recently decreased by 17.05%, indicating that investor sentiment is improving significantly. News and Social Media3.5 / 5News Sentiment1.29 News SentimentBiofrontera has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Biofrontera this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for BFRI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Biofrontera to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biofrontera insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.80% of the stock of Biofrontera is held by insiders.Percentage Held by InstitutionsOnly 10.08% of the stock of Biofrontera is held by institutions.Read more about Biofrontera's insider trading history. Receive BFRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BFRI Stock News HeadlinesBiofrontera Advances Phase 2b Clinical Trial for Ameluz® in Acne Treatment, Final Patient Visit CompletedAugust 25, 2025 | quiverquant.comQBiofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne VulgarisAugust 25, 2025 | globenewswire.comAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.August 29 at 2:00 AM | Paradigm Press (Ad)Rosalind Advisors, Inc. Increases Stake in Biofrontera Inc.August 15, 2025 | gurufocus.comBiofrontera Inc. Reports Revenue Growth Amid Strategic RestructuringAugust 15, 2025 | msn.comBiofrontera Revenue Jumps 15% in Q2August 14, 2025 | theglobeandmail.comBiofrontera Q2 Revenue Jumps 15%August 14, 2025 | theglobeandmail.comBiofrontera Inc. (BFRI) Q2 2025 Earnings Conference Call TranscriptAugust 14, 2025 | seekingalpha.comSee More Headlines BFRI Stock Analysis - Frequently Asked Questions How have BFRI shares performed this year? Biofrontera's stock was trading at $1.09 on January 1st, 2025. Since then, BFRI stock has decreased by 21.9% and is now trading at $0.8515. How were Biofrontera's earnings last quarter? Biofrontera Inc. (NASDAQ:BFRI) issued its quarterly earnings data on Wednesday, August, 13th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by $0.12. The business earned $9.03 million during the quarter, compared to analyst estimates of $8.30 million. Biofrontera had a negative trailing twelve-month return on equity of 1,104.09% and a negative net margin of 42.34%. Read the conference call transcript. When did Biofrontera's stock split? Biofrontera shares reverse split before market open on Wednesday, July 5th 2023.The 1-20 reverse split was announced on Wednesday, July 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Biofrontera IPO? Biofrontera (BFRI) raised $19 million in an initial public offering on Friday, October 29th 2021. The company issued 3,100,000 shares at a price of $5.00-$7.00 per share. Roth Capital Partners and The Benchmark Company acted as the underwriters for the IPO. Who are Biofrontera's major shareholders? Top institutional investors of Biofrontera include Rosalind Advisors Inc. (9.63%) and AIGH Capital Management LLC (9.61%). How do I buy shares of Biofrontera? Shares of BFRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biofrontera own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biofrontera investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NVIDIA (NVDA), NIO (NIO) and Meta Platforms (META). Company Calendar Last Earnings8/13/2025Today8/28/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BFRI CIK1858685 Webwww.biofrontera-us.com Phone781-245-1325FaxN/AEmployees70Year FoundedN/APrice Target and Rating Average Price Target for Biofrontera$2.75 High Price Target$2.75 Low Price Target$2.75 Potential Upside/Downside+223.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($2.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.76 million Net Margins-42.34% Pretax Margin-42.29% Return on Equity-1,104.09% Return on Assets-82.28% Debt Debt-to-Equity Ratio8.99 Current Ratio0.96 Quick Ratio0.75 Sales & Book Value Annual Sales$37.32 million Price / Sales0.23 Cash FlowN/A Price / Cash FlowN/A Book Value($0.46) per share Price / Book-1.85Miscellaneous Outstanding Shares10,140,000Free Float9,652,000Market Cap$8.63 million OptionableNo Data Beta0.50 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:BFRI) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biofrontera Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biofrontera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.